Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Ardelyx Inc (NQ: ARDX )

5.930 USD +0.280 (+4.96%)
Official Closing Price Updated: 4:33 PM EST, Nov 23, 2020 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Ardelyx Inc

< Previous 1 2 3 4 5 Next >
Ardelyx to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today... 
From PR Newswire
Ardelyx to Present at the Jefferies Virtual London Healthcare Conference
Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today... 
From PR Newswire
Ardelyx to Webcast Virtual Analyst Day
--Featuring a panel of distinguished guest speakers-- 
From PR Newswire
Ardelyx Reports Third Quarter 2020 Financial Results and Business Highlights
Tenapanor NDA Accepted for Review by FDA; PDUFA Goal Date set for April 29, 2021 
From PR Newswire
Ardelyx and Kyowa Kirin Highlight New Data Supporting the Clinical Safety and Efficacy of First-In-Class, Phosphate Absorption Inhibitor Tenapanor at ASN's Kidney Week 2020
--Data presented across five posters continue to support the foundational role tenapanorcould play in the treatment of hyperphosphatemia-- 
From PR Newswire
Ardelyx Launches 'Can We Do Better?' Campaign at ASN's Kidney Week 2020
--Campaign highlights Ardelyx commitment to advance the science of phosphate absorption to address significant unmet needs in the current treatment of hyperphosphatemia-- 
From PR Newswire
Ardelyx Announces Data Supporting Efficacy and Safety of Tenapanor, a First-in-Class Phosphate Absorption Inhibitor, to be Presented at ASN's Kidney Week 2020
--Comprehensive datasets demonstrate tenapanor's ability to control serum phosphorous in patients with chronic kidney disease (CKD) on dialysis-- 
From PR Newswire
Ardelyx Announces FDA Acceptance for Filing of its New Drug Application of Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis
NDA Supported by Data from Expansive Clinical Development Program Demonstrating Tenapanor's use as Foundational Therapy 
From PR Newswire
Ardelyx to Participate in Three Upcoming Investor Conferences in September
Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today announced that... 
From PR Newswire
Ardelyx Reports Second Quarter 2020 Financial Results and Recent Business Highlights
Submitted a New Drug Application to the U.S. Food and Drug Administration for the review of tenapanor as a first-in-class therapy to control serum phosphorus in adult patients with chronic kidney... 
From PR Newswire
Ardelyx Selected as a Finalist in the Fierce Innovation Awards for the Development of its First-in-Class Product Candidate Tenapanor
A New Drug Application for the Review of Tenapanor to Control Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis has Been Submitted to the FDA 
From PR Newswire
Ardelyx Announces Submission of New Drug Application to the U.S. FDA for Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis
Application is Supported by Three Positive Phase 3 Clinical Trials for Tenapanor for Hyperphosphatemia, a Condition which affects Approximately 85% of CKD Patients on Dialysis 
From PR Newswire
Ardelyx Announces Positive Second Data Analysis from Ongoing NORMALIZE Phase 4 Study Evaluating Tenapanor in CKD Patients on Dialysis
Foundational use of tenapanor as monotherapy or with sevelamer enabled up to 47.4% of patients to achieve normal serum phosphorus levels (<4.6 mg/dL), a 58% improvement over current standard of care 
From PR Newswire
Ardelyx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases,... 
From PR Newswire
Ardelyx Appoints Veteran Biopharma Executive, Justin Renz, as Chief Financial Officer
Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases,... 
From PR Newswire
Ardelyx to Present at the Jefferies 2020 Virtual Healthcare Conference
Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases,... 
From PR Newswire
Ardelyx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases,... 
From PR Newswire
Ardelyx Strengthens Management Team with Appointment of Susan Rodriguez as Chief Commercial Officer
Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases,... 
From PR Newswire
Ardelyx Reports First Quarter 2020 Financial Results and Recent Business Highlights
Company maintains strong balance sheet with $223.2 million in cash, cash equivalents and short-term investments 
From PR Newswire
Knight Therapeutics Announces Approval of IBSRELA™ in Canada
From GlobeNewswire News Releases
Ardelyx Appoints Onaiza Cadoret-Manier to its Board of Directors
Ardelyx, Inc. (NASDAQ: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with cardiorenal diseases, today... 
From PR Newswire
Ardelyx Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Highlights
Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment choices for people with cardiorenal diseases, today reported... 
From PR Newswire
Ardelyx to Present at the Cowen and Company 40th Annual Health Care Conference
Ardelyx, Inc. (NASDAQ: ARDX) today announced that Mike Raab, president and chief executive officer of Ardelyx, will present at the Cowen and Company 40th Annual Health Care Conference at 8:00 a.m. ET... 
From PR Newswire
Ardelyx to Present at the 9th Annual SVB Leerink Global Healthcare Conference
Ardelyx, Inc. (NASDAQ: ARDX) today announced that Mike Raab, president and chief executive officer of Ardelyx, will present at the 9th Annual SVB Leerink Global Healthcare Conference at 3:30 p.m. ET on... 
From PR Newswire
Ardelyx Announces Pricing of Upsized Public Offering of Common Stock
Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with cardiorenal diseases, today... 
From PR Newswire
Ardelyx Announces Proposed Public Offering of Common Stock
Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with cardiorenal diseases, today... 
From PR Newswire
Ardelyx Announces Positive Topline Results from Pivotal Phase 3 PHREEDOM Study Evaluating Tenapanor in CKD Patients on Dialysis
The primary endpoint was met (p<0.0001) 
From PR Newswire
Ardelyx to Host Conference Call on December 3 to Review Results from the Pivotal Phase 3 PHREEDOM Study
Ardelyx, Inc. (NASDAQ: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with cardiorenal diseases, announced that it will... 
From PR Newswire
Ardelyx to Present at the Piper Jaffray 31st Annual Healthcare Conference
Ardelyx, Inc. (NASDAQ: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with cardiorenal diseases, today announced that Mike... 
From PR Newswire
Ardelyx and Kyowa Kirin Expand Partnership with Two Additional Agreements
- Companies establish a research collaboration with associated options to license any resulting development candidates with the potential for up to $500 million in development and sales milestones for... 
From PR Newswire
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.